Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | ATF1 | P18846 | 4/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
| ▸ | XPO1 | O14980 | 2/20 | 0.30 |
| ▸ | PLAU | P00749 | 1/20 | 0.30 |
| ▸ | JUN | P05412 | 1/20 | 0.30 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.30 |
| ▸ | RELA | Q04206 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20856493 | 0.98 | HTT (0.37) | HTTHSD17B10ATF1NFKB1IDO1 | |
| SCHEMBL30626892 | 0.78 | PLA2G1B (0.35) | HTTIDO1KDM4EMAPTALDH1A1 | |
| SCHEMBL24557904 | 0.78 | PLA2G1B (0.35) | HTTIDO1KDM4EMAPTALDH1A1 | |
| SCHEMBL20856630 | 0.75 | HSD17B10 (0.41) | HTTHSD17B10ATF1NFKB1IDO1 | |
| SCHEMBL17964135 | 0.74 | HTT (0.43) | HTTHSD17B10ATF1NFKB1IDO1 | |
| SCHEMBL25243124 | 0.74 | KDM4E (0.30) | KDM4EMAPTALDH1A1L3MBTL1POLB | |
| SCHEMBL25584916 | 0.72 | HTT (0.42) | HTTHSD17B10ATF1NFKB1IDO1 | |
| SCHEMBL25599692 | 0.72 | HTT (0.42) | HTTHSD17B10ATF1NFKB1IDO1 | |
| SCHEMBL29743287 | 0.72 | HTT (0.42) | HTTHSD17B10ATF1NFKB1IDO1 | |
| SCHEMBL2260139 | 0.71 | PLAU (0.42) | HTTHSD17B10ATF1NFKB1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3947407-B1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL MYERS SQUIBB CO (US) | 2024-06-12 | — | — | EP | disclosed |
| CN-117043156-A | Novel galectin inhibitors of galectins | 格莱克特生物技术公司 | 2023-11-10 | — | — | CN | disclosed |
| EP-4267570-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | Galecto Biotech AB (DK) | 2023-11-01 | — | — | EP | disclosed |
| WO-2023118267-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | GALECTO BIOTECH AB (DK) | 2023-06-29 | — | — | WO | disclosed |
| WO-2022136365-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | GALECTO BIOTECH AB (DK) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022136365-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | GALECTO BIOTECH AB (DK) | 2022-06-30 | — | — | WO | disclosed |
| US-20220185800-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL MYERS SQUIBB CO (US) | 2022-06-16 | — | — | US | disclosed |
| EP-3947407-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | Bristol-Myers Squibb Company (US) | 2022-02-09 | — | — | EP | disclosed |
| CN-113727988-A | Small molecule inhibitors of galectin-3 | 百时美施贵宝公司 | 2021-11-30 | — | — | CN | disclosed |
| US-20210147408-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL MYERS SQUIBB CO (US) | 2021-05-20 | — | — | US | disclosed |
| WO-2020198266-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-10-01 | — | — | WO | disclosed |
| WO-2020198266-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-10-01 | — | — | WO | disclosed |
| WO-2019067702-A9 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-04-25 | — | — | WO | disclosed |
| WO-2019067702-A9 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-04-25 | — | — | WO | disclosed |
| WO-2019067702-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-04-04 | — | — | WO | disclosed |
| WO-2019067702-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220185800-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | LGALS3, LGALS1, LGALS3BP | HTT 3682/4885HSD17B10 3494/4885ATF1 2244/4885 |
| US-20210147408-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | LGALS3, LGALS1, LGALS3BP | HTT 3565/4885HSD17B10 3634/4885ATF1 2130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.